Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors (PIRATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04525014
Recruitment Status : Not yet recruiting
First Posted : August 24, 2020
Last Update Posted : July 21, 2021
Sponsor:
Collaborator:
Texas Children's Cancer Center
Information provided by (Responsible Party):
EpicentRx, Inc.

Brief Summary:
The PIRATE study tests the experimental drug RRx-001 in combination with 2 chemotherapy drugs that are commonly used in patients with cancer. RRx-001 has been used alone and with other anti-cancer medicines in adults. However, the investigators do not know what effects it will have in children and young adults.

Condition or disease Intervention/treatment Phase
Brain Tumor, Recurrent Brain Tumor, Pediatric Central Nervous System Neoplasms Unspecified Childhood Solid Tumor, Protocol Specific Drug: RRx-001 Drug: Temozolomide Drug: Irinotecan Phase 1

Detailed Description:

The goals of the PIRATE study are:

  • Determine if the adult dose of RRx-001 is safe when given together with 2 chemotherapy drugs called irinotecan and temozolomide in children and young adults with previously-treated cancerous tumors
  • Determine the side effects of RRx-001 in children and young adults when given together with irinotecan and temozolomide
  • Understand if the combination of RRx-001, irinotecan, and temozolomide is helpful for children and young adults with previously-treated cancerous tumors
  • In patients with brain tumors, measure if RRx-001 causes changes in the tumor on Magnetic Resonance Imaging (MRI)
  • Determine if RRx-001 causes changes in the immune system which may help the body naturally fight the tumor

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Trial of RRx-001 in Combination With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
Estimated Study Start Date : August 1, 2021
Estimated Primary Completion Date : September 2023
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: RRx-001, Temozolomide and Irinotecan Drug: RRx-001
RRx-001 will be administered every 3 weeks via intravenous infusion at three dose levels: 0.5 mg/m2 (Max 1 mg), 1 mg/m2 (Max 2 mg), and 2 mg/m2 (Max 4 mg).

Drug: Temozolomide
100 mg/m2 (children ≥0.5 m2) or 3 mg/kg (children <0.5 m2) daily for 5 days beginning on day 1 of each cycle

Drug: Irinotecan
90 mg/m2 taken orally daily for 5 days administered 1 hour after temozolomide




Primary Outcome Measures :
  1. Recommended phase 2 dose [ Time Frame: 18 months ]
    Estimate the recommended phase 2 dose of RRx-001 administered every 3 weeks as an IV infusion in combination with oral irinotecan and temozolomide in pediatric patients with recurrent or progressive malignant solid or central nervous system (CNS) tumors.


Other Outcome Measures:
  1. Grade 3 or higher CTCAE version 5.0 adverse event terms [ Time Frame: 18 months ]
    Describe the toxicities of RRx-001 in combination with irinotecan and temozolomide administered on this schedule in this population.

  2. Progression-free survival (PFS) [ Time Frame: 15 months ]
    Describe the anti-tumor effects of RRx-001 in combination with irinotecan and temozolomide administered on this schedule in this population in the context of a Phase 1 trial.

  3. Overall survival (OS) [ Time Frame: 15 months ]
    Describe the anti-tumor effects of RRx-001 in combination with irinotecan and temozolomide administered on this schedule in this population in the context of a Phase 1 trial.

  4. Summarize tumor response rates [ Time Frame: 15 months ]
    Imaging-based evaluation is preferred to evaluation by clinical examination unless the lesion(s) being followed cannot be imaged but are assessable by clinical exam.

  5. Change in tumor perfusion [ Time Frame: 15 months ]
    Measure treatment-induced change in tumor perfusion

  6. Response correlation for change in tumor perfusion [ Time Frame: 15 months ]
    Correlation of change in tumor perfusion to matched patient's best treatment response

  7. Change in cellularity [ Time Frame: 15 months ]
    Measure treatment-induced change in cellularity

  8. Response correlation for change in cellularity [ Time Frame: 15 months ]
    Correlation of change in cellularity to matched patient's best treatment response

  9. Ratio of M1 to M2 peripheral blood circulating monocytes [ Time Frame: 5 months ]
    Assess for change in the ratio of M1 to M2 peripheral blood circulating monocytes over the first 5 cycles of therapy.

  10. Response correlation for ratio of M1 to M2 peripheral blood circulating monocytes [ Time Frame: 5 months ]
    Correlation of change in the ratio of M1 to M2 peripheral blood circulating monocytes over the first 5 cycles of therapy to matched patient's best treatment response.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Recurrent or progressive malignant (World Health Organization (WHO) grade 3 or 4 tumors) primary brain or spinal cord tumors and solid tumors (excluding lymphomas)
  2. Eligible patients may have measureable or non-measurable but evaluable disease according to the reviewed Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.1 criteria.
  3. Patients must have a Karnofsky score of ≥50% if >16 years old or a Lansky score of ≥50 if ≤16 years old
  4. Patients must have fully recovered from the acute treatment-related toxicities (defined as <grade 1) of their most recent prior anti-neoplastic therapy prior to study enrollment.
  5. Patients must be at least 4 weeks from major surgery including craniotomy or tumor debulking/resection and at least 1 week from stereotactic biopsy prior to study enrollment. Patients must have fully recovered from all acute effects of prior surgical intervention excluding central line placement prior to study enrollment. Patients must have fully recovered from all acute effects of central line placement prior to initiation of study treatment.
  6. Patients with neurological deficits should have deficits that are stable for a minimum of 7 days prior to study enrollment. Patients with seizure disorders may be enrolled if the seizures are well-controlled with a stable seizure frequency and duration for a minimum 7 days.
  7. Patients on chronic systemic steroids must be on a stable or decreasing dose for at least 7 days prior to study enrollment. If used to modify immune adverse events related to prior therapy, ≥ 14 days must have elapsed since last dose of corticosteroid.
  8. Platelet count ≥75,000/mm3. Patient must be transfusion independent defined as not receiving platelet transfusions with a 7-day period prior to study enrollment.
  9. Peripheral absolute neutrophil count ≥1000/mm3
  10. Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥50 mL/min/1.73 m2 or a serum creatinine based on age and sex
  11. Conjugated bilirubin ≤1.5 times the institutional laboratory's upper limit of normal
  12. Alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase (SGPT)) ≤3 times the institutional laboratory's upper limit of normal
  13. Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase (SGOT)) ≤3 times the institutional laboratory's upper limit of normal
  14. Adequate pulmonary function defined as:
  15. Oxygen saturation as measured by pulse oximetry > 93% on room air
  16. No evidence of dyspnea at rest
  17. Left ventricular ejection fraction > 50%
  18. Patients of child-bearing potential of both genders must utilize contraception including but not limited to hormonal contraception, barrier method, or abstinence for the duration of the study and 28 days after completion of study.
  19. Patients must have a central line in place prior to administration of the first dose of RRx-001. Patients must have fully recovered from all acute effects of central line placement prior to initiation of study treatment.
  20. The patient or parent/legally authorized representative is able to understand the consent and is willing to sign a written informed consent document according to institutional guidelines. Assent, when appropriate, will be obtained according to institutional guidelines.
  21. Patients must be able to safely take oral medications either as liquid or tablet.

Exclusion Criteria:

  1. Pregnant or breast feeding females
  2. Patients with the following conditions will be excluded from study enrollment: cyanotic heart disease, intermediate or severe β-thalassemia, known glucose-6-phosphate dehydrogenase (G6PD) deficiency, active infections, concurrent malignancy, a known thrombophilia syndrome, or a personal history of venous thromboembolism including catheter-associated thrombi.31-34 Additionally, patients with clinically significant or poorly controlled cardiac, pulmonary, hepatic, or other organ dysfunction that, in the opinion of the investigator, would compromise the patient's ability to tolerate protocol therapy, put them at additional risk for toxicity, or interfere with the study procedures or results are not eligible for study enrollment. Patients with a known coagulopathy or bleeding diathesis or who have undergone either a solid organ or allogeneic bone marrow/stem cell transplant are not eligible for study enrollment.
  3. Patients taking concurrent anti-cancer or investigational drug therapies are not eligible for study enrollment.
  4. Patients taking anti-oxidants including alpha lipoic acid, vitamin E, N- acetylcysteine, and omega 3 fatty acid supplements are not eligible for study enrollment. Patients must be off these drugs for a minimum of 7 days prior to study enrollment and must remain off anti-oxidant medications for the duration of study treatment.
  5. While on study, concomitant use of clozapine, echinacea, leflunomide, natalizumab, and tofacitinib are prohibited due to potential for increased temozolomide toxicity.
  6. Patients who have received drugs that are strong inducers of CYP3A4 within 14 days prior to study enrollment are not eligible.
  7. Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions are not eligible for study enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04525014


Contacts
Layout table for location contacts
Contact: Daniela Westerhold (832) 824-4552 diwester@texaschildrens.org

Locations
Layout table for location information
United States, Texas
Texas Children's Cancer Center
Houston, Texas, United States, 77030
Contact: Daniela Westerhold    832-824-4552    diwester@texaschildrens.org   
Principal Investigator: Holly Lindsey, MD, MS         
Principal Investigator: Patricia Baxter, MD, MBA, MS         
Sponsors and Collaborators
EpicentRx, Inc.
Texas Children's Cancer Center
Investigators
Layout table for investigator information
Study Director: Bryan Oronsky, MD EpicentRx, Inc.
Principal Investigator: Holly Lindsay, MD, MS Texas Children's Cancer Center
Layout table for additonal information
Responsible Party: EpicentRx, Inc.
ClinicalTrials.gov Identifier: NCT04525014    
Other Study ID Numbers: H-45787
First Posted: August 24, 2020    Key Record Dates
Last Update Posted: July 21, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by EpicentRx, Inc.:
Brain cancer
Pediatric cancer
Spinal cord tumor
Solid tumor
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Brain Neoplasms
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Irinotecan
Temozolomide
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents